佐力药业（300181）：拟收购未来医药资产组，丰富公司产品结构

Investment Rating - The report maintains a "Buy" rating for the company, indicating a strong performance relative to the market [6]. Core Insights - The company has signed an acquisition agreement to purchase a multi-element injection asset group from Future Pharmaceutical for a total price of 356 million yuan, which includes both marketed and in-development products [4][6]. - The acquisition is expected to enhance the company's product structure and expand its treatment areas, contributing to a comprehensive health product and service chain covering all age groups [6]. - The market for multi-element injections is projected to reach approximately 1.8 billion yuan in 2024, with the acquired products being recommended in various clinical guidelines, enhancing their market potential [6]. Financial Data and Profit Forecast - Total revenue is forecasted to grow from 2,578 million yuan in 2024 to 4,330 million yuan by 2027, with a compound annual growth rate (CAGR) of approximately 17.9% [5][8]. - The net profit attributable to the parent company is expected to increase from 508 million yuan in 2024 to 1,013 million yuan in 2027, reflecting a CAGR of about 23% [5][8]. - Earnings per share (EPS) are projected to rise from 0.73 yuan in 2024 to 1.44 yuan in 2027 [5][8].